Tackling high-grade neuroendocrine tumors, unlocking the mysteries of kidney cancer metabolism, making comprehensive cancer services more accessible, emerging trends after an FDA committee ruling favors using a new endpoint in multiple myeloma trials, and more are in this month’s tip sheet from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Scientists at the University of California, Riverside, have discovered how adult stem cells retain their regenerative power.

Results from a FAPESP-supported research center pave the way for expanding the use of photodynamic therapy in the fight against skin cancer.

Scientists at St. Jude Children’s Research Hospital implicated the FOXR2 gene in previously unassociated brain tumor types, with implications for diagnosis, prognosis and treatment.  The potentially practice-changing findings were published today in Neuro-Oncology, a journal of the Society for Neuro-Oncology. 

Adapted Argentine tango dance therapy is helping some breast cancer survivors regain natural balance and sensation after experiencing neuropathy, a common side effect of chemotherapy treatment. Expansion of a new clinical study will look further at how this musical movement intervention can “rewire” the brain to improve function after chemotherapy-related nerve changes. 

Imagine tiny LEGO pieces that automatically snap together to form a strong, flat sheet. Then, scientists add special chemical "hooks" to these sheets to attach glowing molecules called fluorophores. University of Missouri researchers have created these tiny, clay-based materials — called fluorescent polyionic nanoclays. They can be customized for many uses, including advancing energy and sensor technology, improving medical treatments and protecting the environment.

The University of Missouri’s transformative initiative to build a new, state-of-the-art research reactor — NextGen MURR — is officially underway with the signing of the first agreement, announced today. Mizzou will partner with a consortium that includes Hyundai Engineering America, the Korea Atomic Energy Research Institute (KAERI), the Hyundai Engineering Company and MPR Associates for the design and licensing of the new reactor.